Evidence map›Paper›PMID 36159610›Full record

ArticleWorld journal of virology2022

Cautious optimism in anticipation of hepatitis B curative therapies.

Alla Turshudzhyan, Micheal Tadros

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alla TurshudzhyanDepartment of Medicine, University of Connecticut, Farmington, CT 06030-1235, United States. turshudzhyan@uchc.edu.
Micheal TadrosDepartment of Gastroenterology and Hepatology, Albany Medical College, Albany, NY 12208, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite relative effectiveness of current hepatitis B therapies, there is still no curative agents available. The new emerging approaches hold promise to achieve cure and loss of hepatitis B surface antigen. Studies or clinical trials investigating new therapies remain small and either focus on patients with low viral load and without hepatotoxic injury or patients with hepatitis D co-infection, which makes it challenging to assess their effectiveness and side effect profile in hepatitis B population.

Indexed as

BulevirtideClustered regularly interspaced short palindromic repeats-associated 9Hepatitis BHepatitis B surface antigen release inhibitorsHepatitis B virusHepatitis B virus entry inhibitorHepatitis B virus transcription inhibitorsNucleocapsid assembly modulatorsTranscription activator-like effector nucleasesZinc-finger nucleases

Identifiers

PMID36159610
PMCPMC9372785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.